Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase NA 1Phase 1 1

Status

Completed 4Withdrawn 1Recruiting 1

Sponsor Class

OTHER 5INDUSTRY 1

Study Type

Interventional 6

Sponsor

Cancer Type

Breast 6Sarcoma 1

Conditions

Breast Neoplasms 6Triple Negative Breast Neoplasms 3Pathologic Complete Response 1Neoplasms 1Neoplasm Metastasis 1Hemangiosarcoma 1Breast Neoplasms, Male 1

Interventions

Trastuzumab 628Paclitaxel 577Cyclophosphamide 555Docetaxel 485Capecitabine 402Letrozole 376Fulvestrant 327Doxorubicin 294Carboplatin 279Tamoxifen 275Anastrozole 243exemestane 228Radiotherapy 218Epirubicin 211Bevacizumab 196palbociclib 189pertuzumab 186Vinorelbine 167Lapatinib 167Gemcitabine 166pembrolizumab 162Surveys and Questionnaires 139Exercise 136Magnetic Resonance Spectroscopy 123Fluorouracil 119Blood Specimen Collection 118eribulin 117Albumin-Bound Paclitaxel 117Drug Therapy 111130-nm albumin-bound paclitaxel 111

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Breast Neoplasms × STA 9090 × Breast × Clear all
NCT01042379 2026-05-06

I-SPY

QuantumLeap Healthcare Collaborative

Phase 2 Recruiting
5,000 enrolled
BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT01560416 2026-03-03

Fulvestrant With or Without Ganetespib in HR+ Breast Cancer

Dana-Farber Cancer Institute

Phase 2 Completed
50 enrolled 14 charts
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT02060253 2018-06-14

Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
9 enrolled
Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT02637375 2016-05-30

A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer

University of Chicago

Phase NA Withdrawn
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01273896 2015-11-20

Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
22 enrolled 6 charts
Breast

Breast Neoplasms

NCT01677455 2015-11-05

Enchant

Synta Pharmaceuticals Corp.

Phase 2 Completed
51 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡